15.07
-0.11(-0.72%)
Currency In USD
| Previous Close | 15.18 |
| Open | 15.18 |
| Day High | 15.46 |
| Day Low | 14.87 |
| 52-Week High | 23.4 |
| 52-Week Low | 3.52 |
| Volume | 552,619 |
| Average Volume | 1.2M |
| Market Cap | 685.23M |
| PE | -14.77 |
| EPS | -1.02 |
| Moving Average 50 Days | 14.97 |
| Moving Average 200 Days | 10.05 |
| Change | -0.11 |
If you invested $1000 in Capricor Therapeutics, Inc. (CAPR) 10 years ago, it would be worth $241.12 as of February 05, 2025 at a share price of $15.07. Whereas If you bought $1000 worth of Capricor Therapeutics, Inc. (CAPR) shares 5 years ago, it would be worth $9,660.26 as of February 05, 2025 at a share price of $15.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Jan 02, 2025 2:15 PM GMT
-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor
Capricor Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Dec 02, 2024 9:15 PM GMT
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is schedul
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
GlobeNewswire Inc.
Nov 20, 2024 2:00 PM GMT
Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular dystrophy in the European regionSAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnolo